Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-ALL.

Perez DR, Nickl CK, Waller A, Delgado-Martin C, Woods T, Sharma ND, Hermiston ML, Loh ML, Hunger SP, Winter SS, Chigaev A, Edwards B, Sklar LA, Matlawska-Wasowska K.

SLAS Discov. 2018 Aug;23(7):732-741. doi: 10.1177/2472555218774248. Epub 2018 May 10.

PMID:
29746793
2.

MLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: a Children's Oncology Group Study.

Matlawska-Wasowska K, Kang H, Devidas M, Wen J, Harvey RC, Nickl CK, Ness SA, Rusch M, Li Y, Onozawa M, Martinez C, Wood BL, Asselin BL, Chen IM, Roberts KG, Baruchel A, Soulier J, Dombret H, Zhang J, Larson RS, Raetz EA, Carroll WL, Winick NJ, Aplan PD, Loh ML, Mullighan CG, Hunger SP, Heerema NA, Carroll AJ, Dunsmore KP, Winter SS.

Leukemia. 2016 Sep;30(9):1909-12. doi: 10.1038/leu.2016.60. Epub 2016 Mar 8. No abstract available.

3.

Pyrosequencing for classification of human FcγRIIIA allotypes: a comparison with PCR-based techniques.

Matlawska-Wasowska K, Gale JM, Nickl CK, Khalili P, Shirley B, Wilson BS, Vasef MA, Winter SS.

Mol Diagn Ther. 2014 Dec;18(6):665-73. doi: 10.1007/s40291-014-0120-5.

PMID:
25230857
4.

Crystal structure of cGMP-dependent protein kinase reveals novel site of interchain communication.

Osborne BW, Wu J, McFarland CJ, Nickl CK, Sankaran B, Casteel DE, Woods VL Jr, Kornev AP, Taylor SS, Dostmann WR.

Structure. 2011 Sep 7;19(9):1317-27. doi: 10.1016/j.str.2011.06.012.

5.

Direct modulation of the protein kinase A catalytic subunit α by growth factor receptor tyrosine kinases.

Caldwell GB, Howe AK, Nickl CK, Dostmann WR, Ballif BA, Deming PB.

J Cell Biochem. 2012 Jan;113(1):39-48. doi: 10.1002/jcb.23325.

6.

Adenosine analogue-oligo-arginine conjugates (ARCs) serve as high-affinity inhibitors and fluorescence probes of type I cGMP-dependent protein kinase (PKGIalpha).

Lavogina D, Nickl CK, Enkvist E, Raidaru G, Lust M, Vaasa A, Uri A, Dostmann WR.

Biochim Biophys Acta. 2010 Sep;1804(9):1857-68. doi: 10.1016/j.bbapap.2010.04.007. Epub 2010 Apr 18.

7.

(D)-Amino acid analogues of DT-2 as highly selective and superior inhibitors of cGMP-dependent protein kinase Ialpha.

Nickl CK, Raidas SK, Zhao H, Sausbier M, Ruth P, Tegge W, Brayden JE, Dostmann WR.

Biochim Biophys Acta. 2010 Mar;1804(3):524-32. doi: 10.1016/j.bbapap.2009.12.004. Epub 2009 Dec 16.

8.

Poly-L-proline type II peptide mimics as probes of the active site occupancy requirements of cGMP-dependent protein kinase.

Zhang R, Nickl CK, Mamai A, Flemer S, Natarajan A, Dostmann WR, Madalengoitia JS.

J Pept Res. 2005 Oct;66(4):151-9.

PMID:
16138853
9.

Inhibition of cGMP-dependent protein kinase by the cell-permeable peptide DT-2 reveals a novel mechanism of vasoregulation.

Taylor MS, Okwuchukwuasanya C, Nickl CK, Tegge W, Brayden JE, Dostmann WR.

Mol Pharmacol. 2004 May;65(5):1111-9.

10.

Exploring the mechanisms of vascular smooth muscle tone with highly specific, membrane-permeable inhibitors of cyclic GMP-dependent protein kinase Ialpha.

Dostmann WR, Tegge W, Frank R, Nickl CK, Taylor MS, Brayden JE.

Pharmacol Ther. 2002 Feb-Mar;93(2-3):203-15. Review.

PMID:
12191612
11.

Highly specific, membrane-permeant peptide blockers of cGMP-dependent protein kinase Ialpha inhibit NO-induced cerebral dilation.

Dostmann WR, Taylor MS, Nickl CK, Brayden JE, Frank R, Tegge WJ.

Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14772-7.

Supplemental Content

Loading ...
Support Center